The role of perforin and granzymes in diabetes

Cell Death and Differentiation

Volumn 17, Issue 4, 2010, Pages 577-585

  Thomas, H E ^a,b   Trapani, J A ^c   Kay, T W H ^a,b  

^a ST VINCENT'S INSTITUTE OF MEDICAL RESEARCH   (Australia)

^b ST VINCENT S HOSPITAL   (Australia)

^c PETER MACCALLUM CANCER CENTRE   (Australia)

Author keywords

Apoptosis; Pancreatic cell; Perforin; Type 1 diabetes

Indexed keywords

GAMMA INTERFERON; GRANZYME B; PERFORIN; SERINE PROTEINASE INHIBITOR; SUPPRESSOR OF CYTOKINE SIGNALING 1; TUMOR NECROSIS FACTOR ALPHA; X LINKED INHIBITOR OF APOPTOSIS;

ALLOTRANSPLANTATION; AUTOIMMUNITY; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL DEATH; CELL DESTRUCTION; CELL KILLING; CELL PROTECTION; CYTOTOXIC T LYMPHOCYTE; DIABETOGENESIS; ENZYME ACTIVITY; GENETIC ASSOCIATION; GRAFT REJECTION; HUMAN; INFLAMMATION; INSULIN DEPENDENT DIABETES MELLITUS; LYMPHOCYTIC INFILTRATION; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PANCREAS ISLET BETA CELL; PANCREAS ISLET TRANSPLANTATION; PRIORITY JOURNAL; PROTEIN DEFICIENCY; PROTEIN FUNCTION; REVIEW; SIGNAL TRANSDUCTION; T LYMPHOCYTE ACTIVATION;

ANIMALS; CELL DEATH; DIABETES MELLITUS, TYPE 1; GRAFT REJECTION; GRANZYMES; HUMANS; INFLAMMATION; INSULIN-SECRETING CELLS; PERFORIN; SIGNAL TRANSDUCTION; T-LYMPHOCYTES, CYTOTOXIC;

MUS;

EID: 77949510984     PISSN: 13509047     EISSN: 14765403     Source Type: Journal    
DOI: 10.1038/cdd.2009.165     Document Type: Review

References (85)

1. Wild S, Roglic G, Green A, Sicree R, King H. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care 2004; 27: 1047-1053.
2. Bolitho P, Voskoboinik I, Trapani JA, Smyth MJ. Apoptosis induced by the lymphocyte effector molecule perforin. Curr Opin Immunol 2007; 19: 339-347.
3. Young LH, Peterson LB, Wicker LS, Persechini PM, Young JD. In vivo expression of perforin by CD8+ lymphocytes in autoimmune disease. Studies on spontaneous and adoptively transferred diabetes in nonobese diabetic mice. J Immunol 1989; 143: 3994-3999.
4. Pietropaolo M, Surhigh JM, Nelson PW, Eisenbarth GS. Primer: immunity and autoimmunity. Diabetes 2008; 57: 2872-2882.
5. Tsai S, Shameli A, Santamaria P. CD8+ T cells in type 1 diabetes. Adv Immunol 2008; 100: 79-124.
6. Bottazzo GF, Dean BM, McNally JM, MacKay EH, Swift PG, Gamble DR et al. In situ characterization of autoimmune phenomena and expression of HLA molecules in the pancreas in diabetic insulitis. N Engl J Med 1985; 313: 353-360.
7. Hanninen A, Jalkanen S, Salmi M, Toikkanen S, Nikolakaros G, Simell O et al. Macrophages T cell receptor usage, and endothelial cell activation in the pancreas at the onset of insulin-dependent diabetes mellitus. J Clin Invest 1992; 90: 1901-1910.
8. Itoh N, Hanafusa T, Miyazaki A, Miyagawa J, Yamagata K, Yamamoto K et al. Mononuclear cell infiltration and its relation to the expression of major histocompatibility complex antigens and adhesion molecules in pancreas biopsy specimens from newly diagnosed insulin-dependent diabetes mellitus patients. J Clin Invest 1993; 92: 2313-2322.
9. Kay TW, Campbell IL, Oxbrow L, Harrison LC. Overexpression of class I major histocompatibility complex accompanies insulitis in the non-obese diabetic mouse and is prevented by anti-interferon-gamma antibody. Diabetologia 1991; 34: 779-785.
10. Katz J, Benoist C, Mathis D. Major histocompatibility complex class I molecules are required for the development of insulitis in non-obese diabetic mice. Eur J Immunol 1993; 23: 3358-3360.
11. Serreze DV, Leiter EH, Christianson GJ, Greiner D, Roopenian DC. Major histocompatibility complex class I-deficient NOD-beta 2-m null mice are diabetes and insulitis resistant. Diabetes 1994; 43: 505-509.
12. Sumida T, Furukawa M, Sakamoto A, Namekawa T, Maeda T, Zijlstra M et al. Prevention of insulitis and diabetes in beta 2-microglobulin-deficient non-obese diabetic mice. Int Immunol 1994; 6: 1445-1449.
13. Wicker LS, Leiter EH, Todd JA, Renjilian RJ, Peterson E, Fischer PA et al. Beta 2-microglobulin-deficient NOD mice do not develop insulitis or diabetes. Diabetes 1994; 43: 500-504.
14. Hamilton-Williams EE, Palmer SE, Charlton B, Slattery RM. Beta cell MHC class I is a late requirement for diabetes. Proc Natl Acad Sci USA 2003; 100: 6688-6693.
15. Kay TW, Parker JL, Stephens LA, Thomas HE, Allison J. RIP-beta 2-microglobulin transgene expression restores insulitis, but not diabetes, in beta 2-microglobulin null nonobese diabetic mice. J Immunol 1996; 157: 3688-3693.
16. de Jersey J, Snelgrove SL, Palmer SE, Teteris SA, Mullbacher A, Miller JF et al. Beta cells cannot directly prime diabetogenic CD8 T cells in nonobese diabetic mice. Proc Natl Acad Sci USA 2007; 104: 1295-1300.
17. Graser RT, DiLorenzo TP, Wang F, Christianson GJ, Chapman HD, Roopenian DC et al. Identification of a CD8 T cell that can independently mediate autoimmune diabetes development in the complete absence of CD4 T cell helper functions. J Immunol 2000; 164: 3913-3918.
18. Nagata M, Santamaria P, Kawamura T, Utsugi T, Yoon JW. Evidence for the role of CD8+ cytotoxic T cells in the destruction of pancreatic beta-cells in nonobese diabetic mice. J Immunol 1994; 152: 2042-2050.
19. Verdaguer J, Yoon JW, Anderson B, Averill N, Utsugi T, Park BJ et al. Acceleration of spontaneous diabetes in TCR-beta-transgenic nonobese diabetic mice by beta-cell cytotoxic CD8+ T cells expressing identical endogenous TCR-alpha chains. J Immunol 1996; 157: 4726-4735.
20. Wong FS, Visintin I, Wen L, Flavell RA, Janeway Jr CA. CD8 T cell clones from young nonobese diabetic (NOD) islets can transfer rapid onset of diabetes in NOD mice in the absence of CD4 cells. J Exp Med 1996; 183: 67-76.
21. Efrat S, Serreze D, Svetlanov A, Post CM, Johnson EA, Herold K et al. Adenovirus early region 3(E3) immunomodulatory genes decrease the incidence of autoimmune diabetes in NOD mice. Diabetes 2001; 50: 980-984.
22. Thomas HE, McKenzie MD, Angstetra E, Campbell PD, Kay TW. Beta cell apoptosis in diabetes. Apoptosis 2009; 14: 1389-1404.
23. Allison J, Thomas HE, Catterall T, Kay TW, Strasser A. Transgenic expression of dominant-negative Fas-associated death domain protein in beta cells protects against Fas ligand-induced apoptosis and reduces spontaneous diabetes in nonobese diabetic mice. J Immunol 2005; 175: 293-301.
24. Apostolou I, Hao Z, Rajewsky K, von Boehmer H. Effective destruction of Fas-deficient insulin-producing beta cells in type 1 diabetes. J Exp Med 2003; 198: 1103-1106.
25. Savinov AY, Tcherepanov A, Green EA, Flavell RA, Chervonsky AV. Contribution of Fas to diabetes development. Proc Natl Acad Sci USA 2003; 100: 628-632.
26. Kanagawa O, Xu G, Tevaarwerk A, Vaupel BA. Protection of nonobese diabetic mice from diabetes by gene(s) closely linked to IFN-gamma receptor loci. J Immunol 2000; 164: 3919-3923.
27. Thomas HE, Parker JL, Schreiber RD, Kay TW. IFN-gamma action on pancreatic beta cells causes class I MHC upregulation but not diabetes. J Clin Invest 1998; 102: 1249-1257.
28. Thomas HE, Irawaty W, Darwiche R, Brodnicki TC, Santamaria P, Allison J et al. IL-1 receptor deficiency slows progression to diabetes in the NOD mouse. Diabetes 2004; 53: 113-121.
29. Kagi D, Ho A, Odermatt B, Zakarian A, Ohashi PS, Mak TW et al. TNF receptor 1-dependent beta cell toxicity as an effector pathway in autoimmune diabetes. J Immunol 1999; 162: 4598-4605.
30. Pakala SV, Chivetta M, Kelly CB, Katz JD. In autoimmune diabetes the transition from benign to pernicious insulitis requires an islet cell response to tumor necrosis factor alpha. J Exp Med 1999; 189: 1053-1062.
31. Eizirik DL, Colli ML, Ortis F. The role of inflammation in insulitis and beta-cell loss in type 1 diabetes. Nat Rev Endocrinol 2009; 5: 219-226.
32. Kagi D, Ledermann B, Burki K, Seiler P, Odermatt B, Olsen KJ et al. Cytotoxicity mediated by T cells and natural killer cells is greatly impaired in perforin-deficient mice. Nature 1994; 369: 31-37.
33. Kagi D, Odermatt B, Seiler P, Zinkernagel RM, Mak TW, Hengartner H et al. Reduced incidence and delayed onset of diabetes in perforin-deficient nonobese diabetic mice. J Exp Med 1997; 186: 989-997.
34. Amrani A, Verdaguer J, Anderson B, Utsugi T, Bou S, Santamaria P et al. Perforin-independent beta-cell destruction by diabetogenic CD8(+) T lymphocytes in transgenic nonobese diabetic mice. J Clin Invest 1999; 103: 1201-1209.
35. Angstetra E, Graham KL, Emmett S, Dudek NL, Darwiche R, Ayala-Perez R et al. In vivo effects of cytokines on pancreatic beta-cells in models of type I diabetes dependent on CD4(+) T lymphocytes. Immunol Cell Biol 2009; 87: 178-185.
36. Badovinac VP, Tvinnereim AR, Harty JT. Regulation of antigen-specific CD8+ T cell homeostasis by perforin and interferon-gamma. Science 2000; 290: 1354-1358.
37. Wang B, Gonzalez A, Benoist C, Mathis D. The role of CD8+ T cells in the initiation of insulin-dependent diabetes mellitus. Eur J Immunol 1996; 26: 1762-1769.
38. Davey GM, Heath WR, Starr R. SOCS1: a potent and multifaceted regulator of cytokines and cell-mediated inflammation. Tissue Antigens 2006; 67: 1-9.
39. Thomas HE, Darwiche R, Corbett JA, Kay TW. Evidence that beta cell death in the nonobese diabetic mouse is Fas independent. J Immunol 1999; 163: 1562-1569.
40. Mueller C, Held W, Imboden MA, Carnaud C. Accelerated beta-cell destruction in adoptively transferred autoimmune diabetes correlates with an increased expression of the genes coding for TNF-alpha and granzyme A in the intra-islet infiltrates. Diabetes 1995; 44: 112-117.
41. Wagner L, Base W, Wiesholzer M, Sexl V, Furnsinn C, Lang G et al. Incidence and phenotype restriction of lymphoid BLT-serine protease granules in spontaneously diabetes prone BB rats compared with a normal rat strain. J Autoimmun 1992; 5: 581-590.
42. Held W, MacDonald HR, Weissman IL, Hess MW, Mueller C. Genes encoding tumor necrosis factor alpha and granzyme A are expressed during development of autoimmune diabetes. Proc Natl Acad Sci USA 1990; 87: 2239-2243.
43. Kelso A, Costelloe EO, Johnson BJ, Groves P, Buttigieg K, Fitzpatrick DR et al. The genes for perforin, granzymes A-C and IFN-gamma are differentially expressed in single CD8(+) T cells during primary activation. Int Immunol 2002; 14: 605-613.
44. Lawrence CW, Braciale TJ. Activation, differentiation, and migration of naive virus-specific CD8+ T cells during pulmonary influenza virus infection. J Immunol 2004; 173: 1209-1218.
45. Dudek NL, Thomas HE, Mariana L, Sutherland RM, Allison J, Estella E et al. Cytotoxic T-cells from T-cell receptor transgenic NOD8.3 mice destroy beta-cells via the perforin and Fas pathways. Diabetes 2006; 55: 2412-2418.
46. Lieberman SM, Evans AM, Han B, Takaki T, Vinnitskaya Y, Caldwell JA et al. Identification of the beta cell antigen targeted by a prevalent population of pathogenic CD8+ T cells in autoimmune diabetes. Proc Natl Acad Sci USA 2003; 100: 8384-8388.
47. McKenzie MD, Dudek NL, Mariana L, Chong MM, Trapani JA, Kay TW et al. Perforin and Fas induced by IFNgamma and TNFalpha mediate beta cell death by OT-I CTL. Int Immunol 2006; 18: 837-846.
48. Kreuwel HT, Morgan DJ, Krahl T, Ko A, Sarvetnick N, Sherman LA et al. Comparing the relative role of perforin/granzyme versus Fas/Fas ligand cytotoxic pathways in CD8+ T cell-mediated insulin-dependent diabetes mellitus. J Immunol 1999; 163: 4335-4341.
49. Oldstone MB, Nerenberg M, Southern P, Price J, Lewicki H. Virus infection triggers insulin-dependent diabetes mellitus in a transgenic model: role of anti-self (virus) immune response. Cell 1991; 65: 319-331.
50. Kagi D, Odermatt B, Ohashi PS, Zinkernagel RM, Hengartner H. Development of insulitis without diabetes in transgenic mice lacking perforin-dependent cytotoxicity. J Exp Med 1996; 183: 2143-2152.
51. Barral AM, Thomas HE, Ling EM, Darwiche R, Rodrigo E, Christen U et al. SOCS-1 protects from virally induced CD8 T cell mediated type 1 diabetes. J Autoimmun 2006; 27: 166-173.
52. Seewaldt S, Thomas HE, Ejrnaes M, Christen U, Wolfe T, Rodrigo E et al. Virus-induced autoimmune diabetes: most beta cells die through inflammatory cytokines and not perforin from autoreactive (anti-viral) CTL. Diabetes 2000; 49: 1801-1809.
53. von Herrath MG, Oldstone MB. Interferon-gamma is essential for destruction of beta cells and development of insulin-dependent diabetes mellitus. J Exp Med 1997; 185: 531-539.
54. Campbell PD, Estella E, Dudek NL, Jhala G, Thomas HE, Kay TW et al. Cytotoxic T-lymphocyte-mediated killing of human pancreatic islet cells in vitro. Hum Immunol 2008; 69: 543-551.
55. Orilieri E, Cappellano G, Clementi R, Cometa A, Ferretti M, Cerutti E et al. Variations of the perforin gene in patients with type 1 diabetes. Diabetes 2008; 57: 1078-1083.
56. Voskoboinik I, Sutton VR, Ciccone A, House CM, Chia J, Darcy PK et al. Perforin activity and immune homeostasis: the common A91V polymorphism in perforin results in both presynaptic and postsynaptic defects in function. Blood 2007; 110: 1184-1190.
57. Voskoboinik I, Thia MC, Trapani JA. A functional analysis of the putative polymorphisms A91 V and N252S and 22 missense perforin mutations associated with familial hemophagocytic lymphohistiocytosis. Blood 2005; 105: 4700-4706.
58. DeFranco S, Bonissoni S, Cerutti F, Bona G, Bottarel F, Cadario F et al. Defective function of Fas in patients with type 1 diabetes associated with other autoimmune diseases. Diabetes 2001; 50: 483-488.
59. Shapiro AM, Lakey JR, Ryan EA, Korbutt GS, Toth E, Warnock GL et al. Islet transplantation in seven patients with type 1 diabetes mellitus using a glucocorticoid-free immunosuppressive regimen. N Engl J Med 2000; 343: 230-238.
60. Sleater M, Diamond AS, Gill RG. Islet allograft rejection by contact-dependent CD8+ T cells: perforin and FasL play alternate but obligatory roles. Am J Transplant 2007; 7: 1927-1933.
61. Sutton VR, Estella E, Li C, Chen M, Thomas HE, Kay TW et al. A critical role for granzyme B, in addition to perforin and TNFalpha, in alloreactive CTL-induced mouse pancreatic beta cell death. Transplantation 2006; 81: 146-154.
62. Ahmed KR, Guo TB, Gaal KK. Islet rejection in perforin-deficient mice: the role of perforin and Fas. Transplantation 1997; 63: 951-957.
63. Sutton R, Gray DW, McShane P, Dallman MJ, Morris PJ. The specificity of rejection and the absence of susceptibility of pancreatic islet beta cells to nonspecific immune destruction in mixed strain islets grafted beneath the renal capsule in the rat. J Exp Med 1989; 170: 751-762.
64. Li B, Hartono C, Ding R, Sharma VK, Ramaswamy R, Qian B et al. Noninvasive diagnosis of renal-allograft rejection by measurement of messenger RNA for perforin and granzyme B in urine. N Engl J Med 2001; 344: 947-954.
65. Vasconcellos LM, Schachter AD, Zheng XX, Vasconcellos LH, Shapiro M, Harmon WE et al. Cytotoxic lymphocyte gene expression in peripheral blood leukocytes correlates with rejecting renal allografts. Transplantation 1998; 66: 562-566.
66. Han D, Xu X, Baidal D, Leith J, Ricordi C, Alejandro R et al. Assessment of cytotoxic lymphocyte gene expression in the peripheral blood of human islet allograft recipients: elevation precedes clinical evidence of rejection. Diabetes 2004; 53: 2281-2290.
67. Estella E, McKenzie MD, Catterall T, Sutton VR, Bird PI, Trapani JA et al. Granzyme B-mediated death of pancreatic beta-cells requires the proapoptotic BH3-only molecule bid. Diabetes 2006; 55: 2212-2219.
68. Youle RJ, Strasser A. The BCL-2 protein family: opposing activities that mediate cell death. Nat Rev Mol Cell Biol 2008; 9: 47-59.
69. McKenzie MD, Carrington EM, Kaufmann T, Strasser A, Huang DC, Kay TW et al. Proapoptotic BH3-only protein Bid is essential for death receptor-induced apoptosis of pancreatic beta-cells. Diabetes 2008; 57: 1284-1292.
70. Casciola-Rosen L, Garcia-Calvo M, Bull HG, Becker JW, Hines T, Thornberry NA et al. Mouse and human granzyme B have distinct tetrapeptide specificities and abilities to recruit the bid pathway. J Biol Chem 2007; 282: 4545-4552.
71. Cullen SP, Adrain C, Luthi AU, Duriez PJ, Martin SJ. Human and murine granzyme B exhibit divergent substrate preferences. J Cell Biol 2007; 176: 435-444.
72. Kaiserman D, Bird CH, Sun J, Matthews A, Ung K, Whisstock JC et al. The major human and mouse granzymes are structurally and functionally divergent. J Cell Biol 2006; 175: 619-630.
73. Mangan MS, Kaiserman D, Bird PI. The role of serpins in vertebrate immunity. Tissue Antigens 2008; 72: 1-10.
74. Zhang M, Park SM, Wang Y, Shah R, Liu N, Murmann AE et al. Serine protease inhibitor 6 protects cytotoxic T cells from self-inflicted injury by ensuring the integrity of cytotoxic granules. Immunity 2006; 24: 451-461.
75. Hui H, Khoury N, Zhao X, Balkir L, D'Amico E, Bullotta A et al. Adenovirus-mediated XIAP gene transfer reverses the negative effects of immunosuppressive drugs on insulin secretion and cell viability of isolated human islets. Diabetes 2005; 54: 424-433.
76. Plesner A, Liston P, Tan R, Korneluk RG, Verchere CB. The X-linked inhibitor of apoptosis protein enhances survival of murine islet allografts. Diabetes 2005; 54: 2533-2540.
77. Shoelson SE, Lee J, Goldfine AB. Inflammation and insulin resistance. J Clin Invest 2006; 116: 1793-1801.
78. Feve B, Bastard JP. The role of interleukins in insulin resistance and type 2 diabetes mellitus. Nat Rev Endocrinol 2009; 5: 305-311.
79. Metkar SS, Menaa C, Pardo J, Wang B, Wallich R, Freudenberg M et al. Human and mouse granzyme A induce a proinflammatory cytokine response. Immunity 2008; 29: 720-733.
80. Tak PP, Spaeny-Dekking L, Kraan MC, Breedveld FC, Froelich CJ, Hack CE et al. The levels of soluble granzyme A and B are elevated in plasma and synovial fluid of patients with rheumatoid arthritis (RA). Clin Exp Immunol 1999; 116: 366-370.
81. Froelich CJ, Pardo J, Simon MM. Granule-associated serine proteases: granzymes might not just be killer proteases. Trends Immunol 2009; 30: 117-123.
82. Lena G, Trapani JA, Sutton VR, Ciccone A, Browne KA, Smyth MJ et al. Dihydrofuro[3,4-c]pyridinones as inhibitors of the cytolytic effects of the pore-forming glycoprotein perforin. J Med Chem 2008; 51: 7614-7624.
83. Stepp SE, Dufourcq-Lagelouse R, Le Deist F, Bhawan S, Certain S, Mathew PA et al. Perforin gene defects in familial hemophagocytic lymphohistiocytosis. Science 1999; 286: 1957-1959.
84. Voskoboinik I, Smyth MJ, Trapani JA. Perforin-mediated target-cell death and immune homeostasis. Nat Rev Immunol 2006; 6: 940-952.
85. Flodstrom-Tullberg M, Yadav D, Hagerkvist R, Tsai D, Secrest P, Stotland A et al. Target cell expression of suppressor of cytokine signaling-1 prevents diabetes in the NOD mouse. Diabetes 2003; 52: 2696-2700.